Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharming GroupPHAR -1.42%77 3-Year EBITDA Growth Rate is -3.90% as of Jun. 2026. GuruFocus rates PHAR with a GF Score™ of 77/100 and a GF Value™ of $13.66 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,130 Biotechnology companies, Pharming Group ranks worse than 73.63% on this metric.
During the past 12 months, Pharming Group's average EBITDA Per Share Growth Rate was 41.70% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was -3.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -19.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Pharming Group was 66.30% per year. The lowest was -109.60% per year. And the median was 12.90% per year.
Pharming Group (NAS:PHAR) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Pharming Group 3-Year EBITDA Growth Rate Related Terms
PHAR vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Pharming Group's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharming Group 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharming Group's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Pharming Group's 3-Year EBITDA Growth Rate falls into.
Pharming Group 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -3.90% mean?
Pharming Group (PHAR) has a 3-Year EBITDA Growth Rate of -3.90% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Pharming Group and its competitors. According to the industry distribution chart, Pharming Group ranks #832 out of 1130 companies in the Biotechnology industry, placing it in the top 73.6%.
Is Pharming Group's 3-Year EBITDA Growth Rate too high?
Pharming Group's current 3-Year EBITDA Growth Rate is -3.90%. Based on the distribution chart, Pharming Group ranks #832 out of 1130 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Pharming Group has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharming Group's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharming Group ranks #832 out of 1130 companies for 3-Year EBITDA Growth Rate. This places Pharming Group in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Pharming Group and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharming Group's current 3-Year EBITDA Growth Rate is -3.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharming Group stock overvalued right now?
Based on GuruFocus' analysis, Pharming Group (PHAR) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.66, compared to a current price of $11.78 — trading 13.8% below its estimated fair value. The current 3-Year EBITDA Growth Rate is -3.90%. Pharming Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Pharming Group (PHAR), the current 3-Year EBITDA Growth Rate is -3.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharming Group (PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued.
The current stock price of $11.78 is trading 13.8% below its estimated GF Value™ of $13.66.
GuruFocus considers Pharming Group to be Modestly Undervalued.
Key valuation signals for PHAR:
3-Year EBITDA Growth Rate: -3.90%
GF Value™: $13.66 vs. price of $11.78 (13.8% below fair value)
No single metric tells the full story. See the PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
77GF Score
Get the complete analysis for PHAR
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHAR has been successfully added to your 
